title: A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants.
abstract: A double-blind, randomised, controlled trial was conducted in 248 British infants to assess the immunogenicity and tolerability of three doses of a meningococcal group C/CRM (197) conjugate vaccine (Lederle Laboratories, USA) given at 2, 3 and 4 months. Control children received three doses of Hepatitis B vaccine (Engerix B(R); SmithKline Beecham). At 5 months of age, 100% of children receiving the conjugate vaccine had specific immunoglobulin G concentrations >2.0 microg/ml (n=116) compared with only 4% of control children (n=121). Those receiving the conjugate also had 2.5- and 1.6-fold higher geometric mean concentrations of PRP and diphtheria antibodies, respectively. The vaccine was well tolerated.
authors.affiliation: Oxford Vaccine Group, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK. menglish@kilifi.mimcom.net
authors.forename: M
authors.initials: M
authors.lastname: English
authors.forename: J M
authors.initials: JM
authors.lastname: MacLennan
authors.forename: J M
authors.initials: JM
authors.lastname: Bowen-Morris
authors.forename: J
authors.initials: J
authors.lastname: Deeks
authors.forename: M
authors.initials: M
authors.lastname: Boardman
authors.forename: K
authors.initials: K
authors.lastname: Brown
authors.forename: S
authors.initials: S
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Buttery
authors.forename: J
authors.initials: J
authors.lastname: Clarke
authors.forename: S
authors.initials: S
authors.lastname: Quataert
authors.forename: S
authors.initials: S
authors.lastname: Lockhart
authors.forename: E R
authors.initials: ER
authors.lastname: Moxon
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood; D001770:Blood Bactericidal Activity; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D022401:Meningococcal Vaccines / Q000009:adverse effects / Q000276:immunology*; D009345:Neisseria meningitidis / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate